Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase 3 1

Status

Unknown 7Recruiting 5Withdrawn 4Completed 3Active not recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Other hematologic neoplasm 1

Conditions

Stomach Neoplasms 1MCRC 1Lymphopenia 1Hematologic Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 563Specimen Handling 493Carboplatin 451Magnetic Resonance Spectroscopy 444Cyclophosphamide 418Cisplatin 405Radiotherapy 353Bevacizumab 314Gemcitabine 313Paclitaxel 298Biopsy 292Drug Therapy 284Blood Specimen Collection 248Capecitabine 246Oxaliplatin 241fludarabine 239Nivolumab 234venetoclax 221Injections 213Docetaxel 211Fluorouracil 206Dexamethasone 188Radiosurgery 182Standard of Care 159Rituximab 159Pemetrexed 156Surgical Procedures, Operative 148atezolizumab 146durvalumab 145Leucovorin 140

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × Thymalfasin × Clear all
NCT06461910 2026-03-03

Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Recruiting
30 enrolled
Gastrointestinal

Stomach Neoplasms

NCT06829355 2025-02-17

THYMI

Beijing Friendship Hospital

Phase 2 Recruiting
52 enrolled

MCRC

NCT06584006 2024-09-19

Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological Tumors

The First Affiliated Hospital of Xiamen University

Phase 2 Recruiting
50 enrolled
Other hematologic neoplasm

Lymphopenia, Hematologic Neoplasms

NCT06598839 2024-09-19

Immuno-effect of Tα1 for Stage I NSCLC

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase NA Recruiting
40 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05086614 2021-10-21

Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer

Fudan University

Phase 3 Recruiting
2,500 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡